CN1159300C - 1-(2,6-二氟苄基)-1h-1,2,3-三唑-4-甲酰胺的结晶改良体及其用作抗癫痫药的用途 - Google Patents

1-(2,6-二氟苄基)-1h-1,2,3-三唑-4-甲酰胺的结晶改良体及其用作抗癫痫药的用途 Download PDF

Info

Publication number
CN1159300C
CN1159300C CNB988056755A CN98805675A CN1159300C CN 1159300 C CN1159300 C CN 1159300C CN B988056755 A CNB988056755 A CN B988056755A CN 98805675 A CN98805675 A CN 98805675A CN 1159300 C CN1159300 C CN 1159300C
Authority
CN
China
Prior art keywords
weak
difluorobenzyl
triazole
carboxamide
moderate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB988056755A
Other languages
English (en)
Chinese (zh)
Other versions
CN1259127A (zh
Inventor
R
R·波特曼
÷
U·C·霍夫梅尔
A·布克哈德
W·谢尔
ά
M·司泽拉吉维茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4209650&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1159300(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1259127A publication Critical patent/CN1259127A/zh
Application granted granted Critical
Publication of CN1159300C publication Critical patent/CN1159300C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNB988056755A 1997-06-10 1998-06-08 1-(2,6-二氟苄基)-1h-1,2,3-三唑-4-甲酰胺的结晶改良体及其用作抗癫痫药的用途 Expired - Lifetime CN1159300C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH1404/1997 1997-06-10
CH140497 1997-06-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNB2004100473675A Division CN1298708C (zh) 1997-06-10 1998-06-08 1－（2，6－二氟苄基）－1h－1，2，3－三唑－4－甲酰胺的结晶改良体及其用途

Publications (2)

Publication Number Publication Date
CN1259127A CN1259127A (zh) 2000-07-05
CN1159300C true CN1159300C (zh) 2004-07-28

Family

ID=4209650

Family Applications (3)

Application Number Title Priority Date Filing Date
CNB2004100473675A Expired - Lifetime CN1298708C (zh) 1997-06-10 1998-06-08 1－（2，6－二氟苄基）－1h－1，2，3－三唑－4－甲酰胺的结晶改良体及其用途
CN988000113A Expired - Lifetime CN1132820C (zh) 1997-06-10 1998-06-08 药物的结晶改良体
CNB988056755A Expired - Lifetime CN1159300C (zh) 1997-06-10 1998-06-08 1-(2,6-二氟苄基)-1h-1,2,3-三唑-4-甲酰胺的结晶改良体及其用作抗癫痫药的用途

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CNB2004100473675A Expired - Lifetime CN1298708C (zh) 1997-06-10 1998-06-08 1－（2，6－二氟苄基）－1h－1，2，3－三唑－4－甲酰胺的结晶改良体及其用途
CN988000113A Expired - Lifetime CN1132820C (zh) 1997-06-10 1998-06-08 药物的结晶改良体

Country Status (36)

Country Link
US (6) US6740669B1 (enExample)
EP (2) EP0994864B1 (enExample)
JP (2) JP3672574B2 (enExample)
KR (2) KR100425656B1 (enExample)
CN (3) CN1298708C (enExample)
AR (4) AR012946A1 (enExample)
AT (2) ATE232852T1 (enExample)
AU (2) AU725517B2 (enExample)
BR (2) BR9804947A (enExample)
CA (3) CA2256013C (enExample)
CO (2) CO4940452A1 (enExample)
CY (1) CY2007014I1 (enExample)
CZ (2) CZ292260B6 (enExample)
DE (3) DE69811500T2 (enExample)
DK (2) DK0994863T3 (enExample)
ES (2) ES2197485T3 (enExample)
FR (1) FR07C0037I2 (enExample)
HU (2) HU226107B1 (enExample)
ID (2) ID21014A (enExample)
IL (2) IL125732A (enExample)
LU (1) LU91345I2 (enExample)
MY (2) MY120156A (enExample)
NL (1) NL300284I2 (enExample)
NO (2) NO329315B1 (enExample)
NZ (2) NZ331371A (enExample)
PE (2) PE79799A1 (enExample)
PL (2) PL192114B1 (enExample)
PT (1) PT994864E (enExample)
RU (2) RU2194041C2 (enExample)
SI (2) SI0994864T1 (enExample)
SK (2) SK283685B6 (enExample)
TR (2) TR199801630T1 (enExample)
TW (2) TW403740B (enExample)
UY (1) UY25844A1 (enExample)
WO (2) WO1998056772A1 (enExample)
ZA (2) ZA984966B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW403740B (en) 1997-06-10 2000-09-01 Novartis Ag Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
PE20040538A1 (es) * 2002-05-31 2004-08-30 Schering Corp Polimorfos inhibidores de xantina fosfodiesterasa v
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
US7875284B2 (en) * 2006-03-10 2011-01-25 Cook Incorporated Methods of manufacturing and modifying taxane coatings for implantable medical devices
US20090069390A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched rufinamide
NZ591725A (en) * 2008-10-13 2012-09-28 Cipla Ltd PROCESS FOR THE PREPARATION OF RUFINAMIDE which is also known as 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
CN101768124B (zh) * 2008-12-30 2012-01-04 北京本草天源药物研究院 一种药物晶体及其制备方法和用途
IT1395736B1 (it) 2009-08-04 2012-10-19 Dipharma Francis Srl Forme cristalline di rufinamide
US8377973B2 (en) * 2009-09-04 2013-02-19 Tactical Therapeutics Inc Compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations
EP2465853A1 (en) * 2010-12-14 2012-06-20 Laboratorios Lesvi, S.L. Polymorph of rufinamide and process for obtaining it
WO2011135105A1 (en) * 2010-04-30 2011-11-03 Laboratorios Lesvi, S.L. Improved process for preparing rufinamide intermediate
ITMI20110718A1 (it) 2011-04-29 2012-10-30 Dipharma Francis Srl Procedimento per la purificazione di rufinamide
US10206874B2 (en) 2012-07-20 2019-02-19 Hetero Research Foundation Rufinamide solid dispersion
WO2021099481A1 (en) 2019-11-20 2021-05-27 Medichem, S.A. Solid composition containing rufinamide

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992378A (en) 1973-12-26 1976-11-16 Eli Lilly And Company Fluoralkyl quinoxadinediones
US4156734A (en) 1976-02-13 1979-05-29 Merck & Co., Inc. Antihypertensive compositions containing an aryl-substituted alanine azo and an arylhydrazino-propionic acid
GB1511195A (en) 1976-10-18 1978-05-17 Ici America Inc Triazole derivatives
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4346097A (en) * 1980-09-30 1982-08-24 Warner-Lambert Company Method for treating convulsions with pyrazole-4-carboxamide derivatives
FI834666A7 (fi) 1982-12-23 1984-06-24 Ciba Geigy Ag Foerfarande foer framstaellning av nya aralkyltriazolfoereningar.
US4789680A (en) * 1982-12-23 1988-12-06 Ciba-Geigy Corporation Aralkyltriazole compounds
US4511572A (en) * 1983-03-18 1985-04-16 The University Of Kentucky Research Foundation Triazoline anticonvulsant drugs
PH22568A (en) * 1985-04-18 1988-10-17 Ciba Geigy Ag Fluorinated benzyl triazoles and pharmaceutical compositions containing the same
CA2002864C (en) 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
JPH02214504A (ja) 1989-02-15 1990-08-27 Nissan Chem Ind Ltd 光学活性キノキサリン化合物の晶析法
JPH04506967A (ja) 1989-07-27 1992-12-03 ジー．ディー．サール　アンド　カンパニー 高血圧症治療用腎選択性生成物
IL96507A0 (en) 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
AU656154B2 (en) 1990-11-06 1995-01-27 Astellas Pharma Inc. Fused pyrazine derivative
JP2753911B2 (ja) 1991-12-06 1998-05-20 キッセイ薬品工業株式会社 Ｎ−ｔｅｒｔ−ブチル−１−メチル−３，３−ジフェニルプロピルアミン塩酸塩の結晶多形およびその製造方法
DE4217952A1 (de) 1992-05-30 1993-12-02 Basf Ag Chinoxalin-2,3(1H,4H)-dione
US5248699A (en) 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
US5631373A (en) 1993-11-05 1997-05-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones
GB9418443D0 (en) 1994-09-13 1994-11-02 Pfizer Ltd Therapeutic agents
GB9419318D0 (en) 1994-09-24 1994-11-09 Pfizer Ltd Therapeutic agents
CN1072215C (zh) 1995-02-22 2001-10-03 赫彻斯特药品和化学品公司 无定形吡咯他尼、吡咯他尼多晶型物,其制备方法和用途
SK283990B6 (sk) * 1996-07-11 2004-07-07 Novartis Ag Spôsob prípravy 1-substituovaných 4-kyano-1,2,3-triazolov, 4-kyano-1-(2,6-difluórbenzyl)-1H-1,2,3-triazol
TW403740B (en) 1997-06-10 2000-09-01 Novartis Ag Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide

Also Published As

Publication number Publication date
CZ253398A3 (cs) 1999-04-14
KR19990087835A (ko) 1999-12-27
JP2000516259A (ja) 2000-12-05
US20060116520A1 (en) 2006-06-01
KR19990087836A (ko) 1999-12-27
NZ331371A (en) 2000-08-25
HK1028241A1 (en) 2001-02-09
ID21014A (id) 1999-04-08
DE69811500T2 (de) 2004-04-01
US7750028B2 (en) 2010-07-06
HK1028242A1 (en) 2001-02-09
AR061004A2 (es) 2008-07-30
DK0994864T3 (da) 2003-07-21
LU91345I2 (fr) 2007-09-04
SI0994863T1 (en) 2003-08-31
IL125733A0 (en) 1999-04-11
HUP0000798A3 (en) 2000-10-30
AR012946A1 (es) 2000-11-22
US20030125568A1 (en) 2003-07-03
CA2256013A1 (en) 1998-12-17
NO329315B1 (no) 2010-09-27
CN1132820C (zh) 2003-12-31
TW403740B (en) 2000-09-01
CY2007014I2 (el) 2009-11-04
ZA984967B (en) 1999-01-11
DE69811500D1 (de) 2003-03-27
WO1998056772A1 (en) 1998-12-17
NO329314B1 (no) 2010-09-27
CO4940448A1 (es) 2000-07-24
SK283685B6 (sk) 2003-12-02
FR07C0037I2 (enExample) 2008-05-16
TR199801631T1 (xx) 1999-06-21
MY125854A (en) 2006-08-30
US6740669B1 (en) 2004-05-25
US20040167186A1 (en) 2004-08-26
PL330764A1 (en) 1999-05-24
DE69813560T2 (de) 2004-02-05
ATE232852T1 (de) 2003-03-15
TW526195B (en) 2003-04-01
CA2256013C (en) 2007-10-16
SK283734B6 (sk) 2003-12-02
WO1998056773A1 (en) 1998-12-17
CA2614926A1 (en) 1998-12-17
NO983666L (no) 1998-12-17
NO983667L (no) 1998-12-17
ZA984966B (en) 1999-01-11
MY120156A (en) 2005-09-30
IL125732A (en) 2002-12-01
PL192114B1 (pl) 2006-08-31
NL300284I2 (nl) 2007-11-01
PL330798A1 (en) 1999-06-07
PL191943B1 (pl) 2006-07-31
EP0994864A1 (en) 2000-04-26
KR100409168B1 (ko) 2004-01-31
TR199801630T1 (xx) 1999-06-21
CN1217716A (zh) 1999-05-26
HK1028031A1 (en) 2001-02-02
CZ292481B6 (cs) 2003-09-17
JP3672574B2 (ja) 2005-07-20
CA2256015A1 (en) 1998-12-17
EP0994863B1 (en) 2003-02-19
SK109398A3 (en) 1998-12-02
JP2000516258A (ja) 2000-12-05
HU225153B1 (en) 2006-07-28
EP0994863A1 (en) 2000-04-26
HUP0002113A3 (en) 2002-09-30
AU8437198A (en) 1998-12-30
CY2007014I1 (el) 2009-11-04
KR100425656B1 (ko) 2004-05-17
HUP0000798A2 (hu) 2000-10-30
AU8437298A (en) 1998-12-30
ES2192779T3 (es) 2003-10-16
IL125732A0 (en) 1999-04-11
US20100310655A1 (en) 2010-12-09
AR012945A1 (es) 2000-11-22
CN1259127A (zh) 2000-07-05
HU226107B1 (en) 2008-04-28
RU2194041C2 (ru) 2002-12-10
US8076362B2 (en) 2011-12-13
DE69813560D1 (de) 2003-05-22
AU725528B2 (en) 2000-10-12
US20010037029A1 (en) 2001-11-01
ES2197485T3 (es) 2004-01-01
BR9804946A (pt) 1999-08-24
SI0994864T1 (en) 2003-10-31
LU91345I9 (enExample) 2018-12-31
NL300284I1 (nl) 2007-10-01
NO983667D0 (no) 1998-08-11
US6455556B2 (en) 2002-09-24
FR07C0037I1 (enExample) 2007-08-17
SK109498A3 (en) 1998-12-02
JP3672575B2 (ja) 2005-07-20
CZ292260B6 (cs) 2003-08-13
HUP0002113A2 (hu) 2001-02-28
PE79799A1 (es) 1999-09-03
EP0994864B1 (en) 2003-04-16
CZ253498A3 (cs) 1999-04-14
ID27660A (id) 2001-04-19
CA2256015C (en) 2008-06-03
BR9804947A (pt) 1999-08-24
CN1298708C (zh) 2007-02-07
AR061005A2 (es) 2008-07-30
CA2614926C (en) 2010-02-09
PE80999A1 (es) 1999-09-06
RU2198167C2 (ru) 2003-02-10
NZ331370A (en) 2000-08-25
NO983666D0 (no) 1998-08-11
DK0994863T3 (da) 2003-05-26
IL125733A (en) 2002-12-01
UY25844A1 (es) 2001-08-27
CN1572789A (zh) 2005-02-02
PT994864E (pt) 2003-07-31
DE122007000051I1 (de) 2007-11-08
DE122007000051I2 (de) 2009-02-19
CO4940452A1 (es) 2000-07-24
AU725517B2 (en) 2000-10-12
ATE237599T1 (de) 2003-05-15

Similar Documents

Publication Publication Date Title
CN1159300C (zh) 1-(2,6-二氟苄基)-1h-1,2,3-三唑-4-甲酰胺的结晶改良体及其用作抗癫痫药的用途
CN1061656C (zh) 制备具有两种晶形的四唑衍生物的方法及所述衍生物的新晶形
CN1125067C (zh) 结晶抗真菌多晶型物
CN1582278A (zh) 多晶型rimonabant,其制备方法及含有它的药物组合物
CN1068878C (zh) 唑酮类氨磺酰衍生物抗螺杆菌剂
EP1212325A2 (en) A novel crystalline form of disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]-pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid salt and processes therefor
CN1181064C (zh) 结晶形式的n－(4－三氟甲基苯基)－5－甲基异噁唑－4－甲酰胺的制备方法
CN1065460A (zh) 衍生于苯并咪唑的新的非镇静抗组胺剂
JP5202129B2 (ja) ５−ヒドロキシ−１−メチルヒダントインの製造方法
CN1656097A (zh) 黄嘌呤磷酸二酯酶v抑制剂多晶型物
EP2563766A1 (en) Improved process for preparing rufinamide intermediate
EP2162453A1 (en) Crystalline form b of olmesartan medoxomil
HK1040078B (zh) 3-(2，4-二氯苄基)-2-甲基-n-(戊璜酰基)-3h-苯并咪唑-5-羧酰胺的晶形
HK1028031B (en) Crystal modification of 1-(2,6-difluorobenzyl)-ih-1,2,3-triazole-4-carboxamide and its use as antiepileptic
CN1432010A (zh) 4－氨基－6,7－二甲氧基－2－(5－甲磺酰氨基－1,2,3,4－四氢异喹啉－2－基)－5－(2－吡啶基)喹唑啉甲磺酸盐及多晶形物
HK1020051A (en) Crystal modification of a pharmaceutical agent
HK1028242B (en) Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic
CN1694884A (zh) Ⅰ晶型、ⅱ晶型、ⅲ晶型泛昔洛韦及其制备方法
JPH029864A (ja) 新規な２−アゾリル−１−シクロプロピルエタノール誘導体およびその塩

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1028031

Country of ref document: HK

C56 Change in the name or address of the patentee

Owner name: NOVARTIS CO., LTD.

Free format text: FORMER NAME: NOVARTIS AG

CP01 Change in the name or title of a patent holder

Address after: Basel

Patentee after: Novartis Ag

Address before: Basel

Patentee before: Novartis AG

CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20040728